The test delivers diagnostics for improved management of immunocompromised patients.

Siemens' molecular imaging technologies are enabling clinicians and researchers to effectively treat within and further explore these areas.

Genzyme announces the availability of two new molecular tests for acute myelogenous leukemia.

CEO Dr. David Tomei to discuss research data and potential product applications of non-Invasive Tr-DNA medical testing technology.

The reagents are designed to detect 23 wild type and mutation sequences associated with cystic fibrosis.

Genzyme's BCR-ABL Mutation Analysis test will assist physicians in evaluating resistance to therapy.

The tests identify non-small cell lung cancer patients likely to respond to therapies.

AutovaxID-C reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches.

The diagnostic kit will be used to predict whether an individual is at risk of having a heart attack.

PRIDE is designed to exploit the growing mass of information on how the body's complement of proteins is altered in many disease states.